Antibacterial Agents TRIZ Cases
- Beta-Lactam–Cannabinoid Conjugates for Oxidative Stress Mitigation
β-Lactam–cannabinoid molecules combine antibacterial action with oxidative-stress control.
- Recombinant YidR Vaccine for Klebsiella Mastitis Control
This case uses recombinant YidR protein with aluminum hydroxide to reduce Klebsiella and E. coli mastitis in dairy cows.
- Commensal Bacteria Antibody Detection for Early B Cell Relapse
Western blot and ELISA detect commensal bacteria-specific antibodies for earlier B cell malignancy diagnosis and relapse detection.
- Nitroimidazole and Nitrofuran Combinations for Tolerant Biofilm Infections
Combining nitroimidazole or nitrofuran prodrugs with low-MIC antibiotics helps eradicate hypoxic biofilms and reduce infection recurrence.
- 9-Aminomethyl Minocycline Therapy for Resistant CABP
Omadacycline combines modified minocycline chemistry with IV-to-oral dosing to target resistant CABP while limiting adverse events.
- Lactococcus Lactis Oral Composition for Skin Bacterial Growth Control
See how Lactococcus lactis JCM5805 supports skin resistance by suppressing pathogens and increasing antibacterial gene expression.
- Prion Protein Complex Infection Therapy Using Sirolimus–Tetracycline
The combination targets B-cell activity and CNS protein synthesis to interrupt amyloid and prion formation.
- Single-Chain Meganucleases for Precise Non-Palindromic DNA Targeting
Linked heterologous subunits enable precise non-palindromic DNA cleavage for targeted recombination with less genome-wide toxicity.
- PD1 and LAG3 Binders Engineered to Reduce Pre-Existing Antibody Binding
PD1 and LAG3 binders reduce pre-existing antibody binding and support T-cell activation.
- PD-0184264 MEK Inhibitor for Delayed Viral Coinfection Treatment
This case uses the MEK-inhibitor metabolite PD-0184264 to extend treatment to 72 hours against resistant viral and bacterial infections.
- Substituted Biphenyl or Phenylheteroaryl Mannosides for FimH Blocking
This case uses substituted mannosides to bind FimH, disrupt bacterial adhesion, and address antibiotic-resistant UTIs.
- Polymicrobial Lactobacillus Composition for Bacterial Vaginosis Treatment
This case combines three to twenty bacterial species, led by L. crispatus, to restore the vaginal microbiome and reduce BV recurrence.
- Dimethylpropylamino Minocycline for Tetracycline-Resistant Infections
A localized dimethylpropylamino substitution creates a minocycline analogue with at least 93.7% clinical success in resistant infections.
- Chimeric Endolysin Domains for Potent Staphylococcus Lysis
Recombinant domain merging improves Staphylococcus killing and protein stability while limiting effects on beneficial microflora.
- Charged Antimicrobial Hydrogel for Ion-Triggered Biofilm Treatment
Electrostatic API binding and ion-triggered release help deliver therapeutic antimicrobial concentrations to chronic wound biofilms.
- Viral Vector Genetic Adjuvants for Dual CD40 and STING Activation
This case combines antigen delivery with LMP1 and IPS1 fusion sequences to strengthen cellular immunity against cancer and infection.
- Pentacyclic Triterpene Furin Inhibitors for Proteolytic Stability
This case uses α- and β-amyrin pentacyclic triterpenes to inhibit furin, limiting pathogen activation without fragile peptidic inhibitors.
- Chloroquinoline Sulfonamide STAT3 Inhibitors for Solubility and Uptake
This case uses heterocyclic and sulfonamide structure changes to support STAT3 inhibition with improved solubility and cellular uptake.